Slide 1: Ersa Phase 2a Study Evaluating TP-03 for MGD with Demodex Mites Topline Data
Ersa Phase 2a Study Evaluating TP-03 for the Treatment of MGD in Patients with Demodex Mites Topline Data Presentation December 2023
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations about future events that we believe may affec
Slide 3: Ersa Phase 2a Study Evaluating TP-03 for Meibomian Gland Disease
Ersa Phase 2a Study Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites • TP-03 (lotilaner ophthalmic solution 0.25%) demonstrated statistically significant improvements compared to baseline in objective measures of meibomian gland function at 6 and 12 weeks
Slide 4: Overview
Ersa Phase 2a Study Overview • Randomized, Double-Masked, Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens (BID vs TID) of TP-03 for the Treatment of MGD in Patients with Demodex mites • 39 patients randomized to BID/TID arms • Endpoints collected included safety assessments, mei
Slide 5: TP-03 Treatment Significantly Improves Meibomian Gland Function
TP-03 Treatment Significantly Improves Meibomian Gland Function • Demonstrated a significant and clinically meaningful increase from baseline that was observed in the mean MGSS of 10.5 (± 1.6 standard error, SE) and 11.7 (± 1.9 SE) for the BID and TID arms, respectively, at Day 85 (p < 0.001) • No s
Slide 6: TP-03 Treatment Significantly Improves Meibomian Gland Secretion
TP-03 Treatment Significantly Improves Meibomian Gland Secretion • Demonstrated improvement in the mean number of meibomian glands secreting clear liquid from baseline that was also statistically significant and clinically meaningful, with an increase of 4.8 (± 0.8 SE) and 5.3 (± 1.1 SE) glands for
Slide 7: MGD Phase 2a Study Safety and Tolerability
Ersa MGD Phase 2a Study Safety and Tolerability • TP-03 was generally well tolerated following 12 week of treatment period – Most Adverse Events (AEs) were mild • 2 Drug-related AEs were mild (5.1%): 1 case of ocular discomfort in the BID arm and 1 case of conjunctivitis in the TID arm • No related